The GoodRx Research team has created a list of the most expensive drugs that takes into account drugs you can get at a pharmacy as well as drugs only a healthcare provider can administer. Some of these drugs can cost almost $1 million or more for a year
In the current global pharmaceutical market, gene therapy drugs occupy a significant portion of the most expensive drug rankings, with five listed in the top ten. Pfizer's recently approved treatment for moderate to severe Hemophilia B, Beqvez, is priced at a staggering $3.5 million, making it...
“We also need greater negotiating powers so that the economic and clinical value of pharmaceutical products can be thoroughly assessed. What we pay as a society should be proportional to the inherent value of a given product.” In May, the House of Representatives in the US passed several ...
aDrug development is by far the most extensive and expensive part of pharmaceutical research. It is the point at which a promising compound is either transformed into a marketable product or shelved. 药物发展显然是配药研究的最广泛和最昂贵的部分。 它是一种有为的化合物被变换成一个有销路的产品或...
And is the world’s most expensive culinary spice largely due to the way it must be grown and harvested (by hand).Saffron has been used for thousands of years as an anxiolytic, sedative, and antidepressant.As a nootropic, Saffron is now used for depression, PMS symptoms, post-partum ...
We created a list of the most expensive drugs by list price, including drugs that are administered under the supervision of a healthcare provider, and obtained typical fill quantities using data and information from the drug manufacturer websites. Using the official manufacturer list price, we calc...
There isn’t much doubt that Glybera’s approval in 2012 was important. It showed that gene therapy, once branded as too risky, could be safe and was ready to be commercialized. Since then, a large number of new companies have been formed and more pharmaceutical firms have shown interest....
Should some method to combat high drug prices materialize, regardless of origin, it would still likely not go into effect for some time, given expected resistance from pharmaceutical companies and the general slow pace of government. For now, patients are stuck fighting their insurance companies to...
have thrown open the market for so-called biosimilars, which are cheaper copies of biologic drugs made from living organisms. The brand-name products—ranging from Humira for rheumatoid arthritis to Avastin for cancer—are high-priced drugs that account for 40 percent of U.S. pharmaceutical sales...
At first impression, the price level of Zolgensma raises many understandable questions, because €1.9 million sounds exorbitantly high in the public domain (often driven by emotions and lack of specialised knowledge of the costs and risk of the development of a new pharmaceutical). However, ...